Sun Pharma gains on higher prices for drugs

Fri Feb 22, 2013 1:44pm IST

Related Topics

Stocks

   

Reuters Market Eye - Shares in Sun Pharmaceutical Industries(SUN.NS) gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries (TARO.N) has pushed through price increases in three products last week, citing industry checks.

Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales.

The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds.

Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro.

(Reporting by Abhishek Vishnoi)

FILED UNDER:
  • Most Popular
  • Most Shared

Banking

REUTERS SHOWCASE

Tobacco Control

Tobacco Control

India moves toward ban on loose cigarettes to deter smoking   Full Article 

Pressure on RBI

Pressure on RBI

Exclusive - RBI under pressure to cut rates as growth slips  Full Article 

Asset Sale Dates

Asset Sale Dates

India yet to decide on dates for key asset sales - official   Full Article 

Women on Boards

Women on Boards

Germany to introduce legal quotas for women on company boards  Full Article 

OPEC Oil Talks

OPEC Oil Talks

Saudi, Russia pre-OPEC talks yield no oil output cut  Full Article 

India-U.S. Trade

India-U.S. Trade

India, U.S. hold first trade dialogue in four years  Full Article 

SAARC Summit

SAARC Summit

China looms over SAARC summit in the Himalayas  Full Article 

Microsoft in China

Microsoft in China

Microsoft to pay China $140 million for 'tax evasion'   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage